LG and chest CT were identified. Two of these patients also had FDG-PET. Imaging features of LG on CT and PET were reviewed. Results: Pulmonary nodules or masses with peribronchovascular, subpleural, and lower lung zonal preponderance were present in all patients. Central low attenuation (4 of 4 patients), ground-glass halo (3 of 4 patients), and peripheral enhancement (4 of 4 patients) were observed in these nodules and masses. An air-bronchogram and cavitation were seen in three of four patients. FDG-PET scans demonstrated avid FDG uptake in the pulmonary nodules and masses. Conclusion: Pulmonary LG presents with nodules and masses with a lymphatic distribution, as would be expected for a lymphoproliferative disease. However, central low attenuation, ground-glass halo and peripheral enhancement of the nodules/masses are likely related to the angioinvasive nature of this disease. Peripheral enhancement and ground-glass halo, in particular, are valuable characteristic not previously reported that can help radiologists suggest the diagnosis of pulmonary LG.
INTRODUCTION
Lymphomatoid granulomatosis (LG) is a rare, aggressive, Lymphomatoid Granulomatosis: CT and FDG-PET Findings angiodestructive, extranodal Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disease with reactive T-cells (1) . Reactive T-cells often predominate in the background, and therefore, LG was first thought to be a T-cell disorder. First described in 1972, LG was initially categorized as a subset of pulmonary granulomatous vasculitis (2) . Prior names for LG include angiocentric lymphoma and angiocentric immunoproliferative lesion, which reflect the vascular-centered morphology of abnormal cells on pathology.
Though the imaging appearance of LG on chest radiography has been described in multiple series, the CT appearance of pulmonary LG has not been well delineated (3) (4) (5) (6) . To our knowledge, only one other cases series has kjronline.org 672
Chung et al. studied the CT appearance of pulmonary LG (7) . Most descriptions of CT and fluorodeoxyglucose positron emission tomography (FDG-PET) appearance of LG were presented in isolated case reports (8) (9) (10) . The purpose of our study was to analyze the CT and FDG-PET findings in patients with pathologically proven pulmonary LG.
MATERIALS AND METHODS
A retrospective review of patient data and of radiological studies was approved by our Institutional Review Board. No patient consent was required for this Health Insurance Portability and Accountability Act (HIPAA)-compliant study. Between 2000 and 2009, four patients with pathologically proven pulmonary LG and chest CT scans within two weeks of pathological diagnosis were identified by a database search of the radiology and pathology reports at our institution. Medical records were reviewed to determine patient age, gender, initial presentation, medical history, grade of LG, means of tissue diagnosis, and treatment regimen.
Tissue diagnosis and grading of cases was based on the 2008 WHO classification (11) . In three of the patients, the diagnosis was made based on the surgical wedge resection of pulmonary nodules and masses. In one of the patients, the diagnosis was initially made by a liver biopsy, and pulmonary involvement was later confirmed at the autopsy.
Two of the three patients also underwent FDG-PET scans prior to initiation of treatment. In one of these two patients, the initial PET scan was performed within three weeks of the chest CT. The follow-up PET of this patient and all three of the PET studies of the other patient were performed by concurrent CT.
CT scans of the chest from 2001 to 2009 were performed on various multi-detector CT scanners. The CT parameters ranged from 120-140 kVp, 260 to 432 mA, and 2.5 to 5 mm slice thickness reconstruction; two of these patients had CT scans performed with automatic tube current modulation. All scans were performed with IV contrast. Images were reviewed in the lung, soft tissue, and bone windows. PET scans were performed 60 minutes after injection of approximately 15 mCi of F-18 FDG; tomographic images of the body from the neck to the proximal thigh were acquired in 3D mode on either a Siemens HR+ PET scanner, Siemens Biograph 64 (Siemens Medical Systems, Erlangen, Germany), or GE Discovery 64 PET/CT scanner (GE Medical Systems, Milwaukee, WI). Standardized uptake values (SUV) were determined as the maximum value within the lung tumors, as a function of body weight. PET and CT images were displayed and registered on a Siemens Multimodality Workstation using True-D imaging software.
CT scans were reviewed retrospectively by two boardcertified, fellowship-trained chest radiologists who were aware of the diagnosis of LG in these patients. Disagreements were resolved by consensus. Data recorded from the CT scans included the number and size range of the lung nodules or masses. The presence of cavitation or central air density, central low attenuation defined as < 20 Hounsfield unit, air bronchograms, ground-glass halo, and peripheral enhancement of the nodule or masses was recorded. Other findings such as ground-glass opacities, interlobular and intralobular septal thickening, consolidation, lymphadenopathy, and pleural effusions were also recorded. The axial (peribronchovascular, subpleural, or random) and craniocaudal (upper, mid, lower) distribution of the disease was documented. Follow up CT scans were also reviewed Note.-CXR = chest X-ray, EPOCH = Etoposide, Prednisone, Vincristine (Oncovin), Cyclophosphamide, Doxorubicin (Hydroxydoxorubicin), R-CHOP = Rituximab-Cyclophosphamide, Doxorubicin (Hydroxydoxorubicin), Vincristine (Oncovin), Prednisone to determine if there was a response to treatment. In cases where FDG-PET was performed, activity within the nodules was assessed in conjunction with a board certified, fellowship-trained nuclear medicine physician. Because of the small number of patients in the study, statistical analyses were not warranted.
RESULTS
Patient demographics, clinical presentations, and disease course are as summarized in Table 1 . The mean age of the patients was 52 year old. All four patients were men. No affected patients were immunocompromised. Patient 3 had a history of congenital deafness. Clinical presentation ranged from relatively mild respiratory symptoms to highly symptomatic systemic manifestations. All patients in our series were treated with chemotherapy. Two of the patients responded to chemotherapy, whereas two of the patients had progressive disease.
The pathological diagnosis of LG was made based on a surgical biopsy specimen. Three of the patients had CTguided percutaneous needle aspirate/biopsy of the lung nodules/masses, which did not result in the specific diagnosis of LG prior to surgical biopsy. Patient 1 had a histological grade of 2, patient 2 had a histological grade of 3, and patients 3 and 4 had histological grades of 1 which eventually progressed to grade 3.
The main findings on chest CT are as summarized in Table  2 . Selected pertinent images of each patient are included in Figures 1-4 . Pulmonary nodules and masses seen in all of the patients, multiple nodules and masses seen in three of the patients, and solitary nodules and masses in one of the patients. The nodules and masses were lower-lobe predominant with a peribronchovascular and/or subpleural distribution in the axial plane.
All four of the patients had nodules or masses that demonstrated peripheral enhancement, central low attenuation, and ground-glass halo. Air-bronchograms were present in three patients, whereas cavitary nodules/masses were present in two patients.
Avid FDG uptake was present in both patients (patient 1 and 2) who had FDG-PET (Figs. 1, 2 ). Nodules and masses larger than 2 cm in both patients demonstrated a paucity of central FDG uptake. For patient 1, the maximum SUV within the pulmonary nodules/masses at baseline was 7.3; whereas, the maximum SUV within pulmonary nodules/masses on follow up scan (58 days later) had decreased to 3.5 post Note.-PBV = peribronchovascular treatment. For patient 2, the maximum SUV within the pulmonary nodules/masses at baseline was 10.8; whereas, the maximum SUV within the pulmonary nodules/masses on post-treatment scan (39 days later) had decreased to 4.3. FDG uptake was seen in the left chest wall mass and hepatic lesions of patient 1. No FDG avidity was present in mediastinal or hilar lymph nodes in either patient; even though patient 2 had mildly enlarged mediastinal nodes.
DISCUSSION
Lymphomatoid granulomatosis is an angiodestructive EBVpositive lymphoproliferative disease, which clinically and histologically, can mimic pulmonary lymphoma and Wegener granulomatosis (WG). Affected patients often present with non-specific symptoms such as cough, shortness of breath, chest pain, and B symptoms (fever, weight loss, malaise) (2), as in our series. LG primarily affects the pulmonary system; however, it can also affect the skin (39% of cases), the nervous system (30% of cases), kidneys, liver, and GI tract (12) . In our series, two of the four patients had hepatic involvement. In addition, affected patients are often immunocompromised (Wiskott-Aldrich syndrome, human immunodeficiency virus [HIV], or lymphoma) though none of them were immunocompromised in our study. Prognosis is poor with up to two of three of patients dying within the first year of diagnosis; typically due to secondary infection (12) .
Gross pathological specimens are significant for centrally necrotic nodules. Angiodestructive and angioinvasive polymorphic lymphoid infiltration is common, and is composed mainly of lymphocytes (mainly reactive T-cells, histology, which eventually progressed to grade 3 histology.
Many of the findings in our study are similar to those previously reported in the radiology literature (3, 4, (7) (8) (9) 14) . As in other studies, our patients had pulmonary nodules or masses, with a lower lung preponderance. In addition, most of the cases in our series demonstrated a peribronchovascular preponderance of pulmonary nodules as described in the only other series studying the CT appearance of pulmonary LG (7) . The propensity of pulmonary LG in our study to affect peribronchovascular and subpleural regions, which corresponds to a perilymphatic distribution, is as expected for a lymphoproliferative disorder. Internal air bronchograms in nodules and masses, seen in three of our patients with LG, also has also been described previously (7) . An air-bronchogram has also been described in the setting of infection, with bronchogenic lung cancer (typically bronchioloalveolar cell carcinoma) (8, 9, 14, 15) , lymphoma, and WG (16) (17) (18) (19) . A low attenuation center and central cavitation of nodules/masses, seen in our study, has also been previously reported (3) , and correspond to the histological findings of central necrosis.
To our knowledge, the ground-glass halo and peripheral enhancement of pulmonary nodules and masses have not been specifically described in LG. Initially described in angioinvasive aspergillosis (17) , ground-glass halo was thought to represent a specific finding. Many other conditions have now been associated with this CT manifestation (20) . Pathologically, the surrounding halo of ground-glass opacities may represent hemorrhage, inflammation, or tumor spread. Three out of four patients in our series had nodules or masses demonstrating the halo sign. Given LG's angioinvasive nature, the areas of ground-glass surrounding nodules or masses likely represent hemorrhage. Peripheral enhancement of the nodules/masses was seen in all of the patients in our study in the majority of nodules and masses. The peripheral enhancement is also likely related to the angio-invasive and angio-destructive nature of the LG.
A high index of suspicion for LG based on the combination of CT findings may have significant implications in further work-up and management of patients. In our series, the final diagnosis of LG in all four cases was made based on a surgical biopsy or autopsy specimen. Three of four patients underwent a CT-guided core needle biopsy, which did not yield the specific diagnosis of LG, possibly due to largely necrotic centers of these lesions. In addition, suspicion based on CT findings can also help guide and prompt specific immuno-staining for B-cell lymphocyte markers and in situ hybridization of EBV encoded RNA (EBER) to aid the diagnosis of this rare entity (Fig. 5) .
All previously described cases of FDG PET in the setting of LG have shown increased uptake in pulmonary nodules and masses (8, 9, 14, 15) . Only in one case report is there a suggestion of peripheral uptake in the walls of the cavitary pulmonary lesions (14) . Nodules and masses larger than 2 cm in our study demonstrated the paucity of central FDG uptake, consistent with the histological finding of central necrosis. After treatment, the maximum SUV within the pulmonary nodules/masses decreased, suggesting a response to treatment.
Coarse linear opacities described by Lee et al. (7) were not a major finding in our series. Though never explicitly stated, the linear opacities in their series may have represented a healing phase of nodules and masses as coarse linear opacities that became more prominent with the treatment of pulmonary LG in one of their patients. The CT scans included in our study were performed within two weeks of pathological diagnosis; Lee et al. (7) may have been more inclusive in the CT scans they included if the timing of imaging relative to pathological diagnosis in their series had been reported. Also, the reverse halo sign (central focus of ground-glass opacity surrounded by a rim of consolidation) has also been described in the setting of pulmonary LG (21) . None of our cases demonstrated this unusual finding.
Pulmonary LG shares many of the same imaging manifestations of more common pulmonary conditions such as WG and pulmonary lymphoma, and should be considered when these more common diagnoses have been excluded. This is especially true in patients with underlying immunosuppression (Wiskott-Aldrich syndrome, HIV, or lymphoma) as well as in patients with concomitant brain lesions. The combination of lower lung predominant peribronchovascular or subpleural pulmonary nodules and masses with central low attenuation, ground-glass halo, and peripheral enhancement should prompt consideration of this rare entity.
